GALE Share Price

Open 1.74 Change Price %
High 1.75 1 Day -0.06 -3.43
Low 1.68 1 Week -0.22 -11.52
Close 1.69 1 Month -0.39 -18.75
Volume 444309 1 Year 0.93 122.37
52 Week High 4.75
52 Week Low 0.16
GALE Important Levels
Resistance 2 1.75
Resistance 1 1.73
Pivot 1.71
Support 1 1.65
Support 2 1.63
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
DRYS 1.01 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
CPSL 0.10 66.67%
LOCM 0.09 50.00%
GLBS 9.70 31.79%
LTRE 2.85 29.55%
ETRM 7.96 29.22%
INFI 2.00 29.03%
QKLS 0.14 27.27%
PRKR 2.57 26.60%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
More..
NASDAQ USA Top Losers Stocks
HEAT 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Galena Biopharma, Inc. (NASDAQ: GALE)

GALE Technical Analysis 1.5
As on 20th Jan 2017 GALE Share Price closed @ 1.69 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.20 & Sell for SHORT-TERM with Stoploss of 2.11 we also expect STOCK to react on Following IMPORTANT LEVELS.
GALE Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
GALE Other Details
Segment EQ
Market Capital 139060160.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.galenabiopharma.com
GALE Address
GALE
4640 SW Macadam Avenue
Suite 270
Portland, OR 97239
United States
Phone: 855-855-4253
Interactive Technical Analysis Chart Galena Biopharma, Inc. ( GALE NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Galena Biopharma, Inc.
GALE Business Profile
Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). In January 2014, Galena Biopharma Inc acquired Mills Pharmaceuticals, which has the worldwide rights to GALE-401 (Anagrelide CR), a patented, controlled release formulation of anagrelide.